Search results
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 2 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 5 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Cancer drug trial provides lessons for future
Medical Xpress· 2 days agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Char-Koosta News· 2 days agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc....
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
Analysts Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $251.70
ETF DAILY NEWS· 5 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports ...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 5 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its ...
Merck beats earnings forecasts as cancer drug sales boom
Crain's New York Business· 2 days agoThe guidance comes as Merck’s first-quarter earnings topped $15.8 billion, a 9% increase from the...
BeiGene (NASDAQ:BGNE) Trading Down 2.4%
ETF DAILY NEWS· 6 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report)’s stock price dropped 2.4% during trading on Friday . The company traded as low as $126.97 and last traded at $128.77. Approximately 17,319 shares ...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 2 days agoShanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...